Drugs / TLD-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03387917 | Nov 2018 → Sep 2023 | cancer | Swiss Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLD-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03387917 ↗ |
| Route | Intravenous | “TLD-1 was administered intravenously every 3 weeks up to a maximum of 9 cycles (6 for patients with prior anthracyclines) from a starting dose of 10mg/m2, according to an...” PMID 38377773 ↗ Feb 2024 |